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Abstract
Emerging of the COVID-19 pandemic has raised interests in the field of biology and pathogenesis of coronaviruses; includ-
ing interactions between host immune reactions specific, and viral factors. Deep knowledge about the interaction between 
coronaviruses and the host factors could be useful to provide a better support for the disease sufferers and be advantageous 
for managing and treatment of the lung infection caused by the virus. At this study, we reviewed the updated information on 
the pathogenesis of the COVID-19 and the immune responses toward it, with a special focus on structure, genetics, and viral 
accessory proteins, viral replication, viral receptors, the human immune reactions, cytopathic effects, and host-related factors.
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Introduction
Coronaviruses belong to the enveloped RNA viruses with a 
positive sense and non-segmented genome [1]. Until now, 
coronaviruses including Middle Eastern respiratory syn-
drome coronavirus (MERS-CoV), Severe acute respiratory 
syndrome coronavirus (SARS-CoV), and Severe acute res-
piratory syndrome coronavirus 2 (SARS-CoV-2) [Casituve 
agent of coronavirus 2019 (COVID-19)] are known to infect 
the human and cause respiratory disorders with high patho-
genesis that led to regional and global outbreaks [2]. The 
coronaviruses are categorized into the Nidovirales orders, 
Coronaviridae family, and Coronavirinae subfamilies, 
which this subfamily include four genera: α-coronavirus, 
β-coronavirus, γ-coronavirus, and δ-coronavirus [3].
From November 2002 to June 2003, a viral respiratory 
disorder emerged in southern China and rapidly spread the 
other countries, resulting in more than 8000 confirmed cases 
[4]. SARS patients exhibit flu-like symptoms and pneumonia 
that in severe circumstances cause lethal respiratory fail-
ure and acute distress syndrome. In 2012, MERS-CoV was 
reported from Saudi Arabia as a causative agent of respira-
tory malady, similar to SARS, causing two major outbreaks 
in Saudi Arabia (2012) and South Korea (2015), resulting 
in over 2000 confirmed cases [5]. Previously, two corona-
viruses (HCoV-229E and HCoV-OC43) have been identi-
fied to cause mild upper respiratory symptoms, although 
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sometimes they cause severe low respiratory infection in the 
elderly, infants, as well as immunocompromised individu-
als. COVID-19 is a new infection that was first reported on 
31 December 2019 (Wuhan, Hubei Province, China), that 
could cause a respiratory malady (influenza-like disorder) 
with symptoms such as dry cough, fever, tiredness, head-
ache, diarrhea, sore throat and, in more severe cases it could 
induce pneumonia [6]. Until 31 May 2020, over 5,934,936 
confirmed COVID-19 cases and 367,166 approved mortality 
were recorded worldwide by more than 216 countries, areas, 
or regions [7].
In spite of the not completely clear pathologies mecha-
nism of COVID-19 infection, viral, and host-related factors 
are known to be crucial in the infection process. During 
COVID-19 infection, host factors stimulate the immune 
responses to the SARS-CoV-2 virus. Meanwhile, it has to 
be considered that immunopathogenesis is correlated with 
an out-of-control immune response, which may lead to pul-
monary tissue injury. Therefore, there is an urgent need to 
better understanding of the interactions among host immune 
responses and viral factors of SARS-CoV-2 as well as host-
related factors that will offer fundamental insights into the 
treatment and control of the disease. In this study, we first 
review the literature of the SARS-CoV-2 proliferation cycle, 
then summarize the current information of critical immune 
reactions activated during COVID-19 infection.
Structure, genetics and viral accessory 
proteins
The positive-sense RNA genome (30 kb) of SARS-CoV-2 
contains a 5′ cap construct conjoint with a 3′ poly-A tail 
that allows performing as mRNA for translating replicate 
polyproteins. The 5′ end of the genome has a leader and 
untranslated region (UTR) sequence that comprises the com-
positions required for transcription and replication of RNA. 
The SARS-CoV-2 genome organization is 5′-leader-UTR-
replicase-S-E-M–N-3′ UTR-poly A with intrinsic genes 
inside the structural genes at the 3′ end of the genome [3, 
8, 9]. SARS-CoV-2 has a pleomorphic morphology with a 
diameter of 60–120 nm [3, 9]. The genome of SARS-CoV-2 
is positive, sensitive, non-fragmented RNA, with an aston-
ishingly large size in a range of 27 to 32 kb [8, 9].
Genomic RNA of the SARS-CoV-2 virus contains five 
caped and 3-polyadenylated, including seven Open Read-
ing Frames (ORF). ORF 1a and 1b comprise two-thirds of 
the virus genome, encoding unstructured poly-proteins. The 
rest of ORFs code structural proteins such as spike protein 
(S), envelopes protein (E), membrane protein (M) as well as 
nucleocapsid protein (N). Additionally, in some cases the 
hemagglutinin esterase (HE) gene is located between ORF 
1b and ORF S. The structural proteins fold and enter into 
endoplasmic reticulum and transport to the transitional gap 
of endoplasmic Reticulum-Golgi. The SARS-CoV-2 replica-
tion cycle has steps including; attachment and penetrance, 
replication of virus replication, genome transcription and 
replication, structural protein translation, assemblage and 
discharging the virus [8–10]. Figure 1 presents a schematic 
overview of the SARS-CoV-2 replication cycle.
The noticeable characteristic of coronaviruses is the spike 
proteins in a club-shaped form that give them the shape of 
a solar corona. The M protein is a common marker in the 
virion, which is a small (30 kDa) structure encompassing 
three transmembrane domains and a short N-terminal gly-
cosylated ectodomain and a very larger C-terminal endodo-
main [8, 9]. Currently, it has been suggested that this protein 
could adopt two distinct conformations; enabling to improve 
membrane shape, along with attachment to the nucleocapsid 
[3].
Protein E of the SARS-CoV-2 virus (12 kDa) is a trans-
membrane structure with an N-terminal ectodomain and a 
C-terminal endodomain, having an ion channel action. Addi-
tionally, this construct promotes the assembly and discharge 
of the virus. The N protein is a unique construct within the 
nucleocapsid which includes one N-terminal and a C-termi-
nal domain. Besides, this protein is phosphorylated which 
improves the affinity for RNA of viruses compared with the 
other non-viral RNAs. N protein attaches the viral genome 
with a beads-on-a-string type pattern. Another structural 
viral protein is HE which exists in β-coronaviruses and 
plays as a hemagglutinin that attaches to sialic acid on host 
glycoproteins and contains acetyl-esterase activity, which is 
suggested to enhance the cell entry mediated to S protein and 
viral spread via the host mucus [3, 8, 9, 11].
Viral replication
Following the receptor attachment, SARS-CoV-2 needs to 
reach the host cell cytosol. Binding is performed via S pro-
tein cleavage by a cathepsin, followed by cell membrane 
fusion. Cleavage is carried out at two sites in the S2 seg-
ment, and fusion occurs inside acidic endosomes, but some 
coronaviruses like murine coronavirus, so-called mouse 
hepatitis virus (MHV), could fuse into the host plasma 
membrane [3, 11–13]. The next step is the translation of the 
replicase gene (encodes two big ORFs) from genomic RNA 
in the virion [11].
These ORFs (rep1a and rep1b) form two polyproteins, 
pp1a and pp1ab, use a slippery sequence (5′-UUU AAA 
C-3′) and an RNA pseudoknot is performed which trig-
gers the ribosomal frameshift of the rep1a reading frame to 
the rep1b. Polyproteins pp1a compromise the eleven non-
structure proteins (NSPs) including nsps 1 to nsps 11, while 
pp1ab compromise nsps 1 to nsps 16. Coronaviruses encode 
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proteases, for example, papain-like proteases, coded by nsp3, 
and a serine-type protease, the major protease, coded by 
nsp5 gene. At the next step, the nsps move inside the repli-
case-transcriptase complex to form an environment for syn-
thesis and replication of RNA, as well as sub-genomic RNAs 
transcription. Synthesis of viral RNA forms sub-genomic 
and genomic RNAs. Sub-genomic RNAs provide mRNAs 
for transcription of the structural and accessory genes that 
are located downstream of the replicase polyproteins. Also, 
it has been shown that coronaviruses can recombine using 
non-homologous and homologous recombination [11–13].
Upon replication and subgenomic RNA synthesis, the 
structural proteins, including S, E, and M, are entered into 
the endoplasmic reticulum and migrate inside the secretory 
pathway within the Endoplasmic Reticulum-Golgi Interme-
diate Compartment (ERGIC), where genomes encapsidated 
by N protein fuse into ERGIC membranes which contains 
structural proteins, and form mature virions [3].
The M proteins, along with E proteins, prompt pro-
tein–protein cooperation that is necessary for coronaviruses 
assembly [11–13]. N proteins increase the production of 
virion like particles (VLPs), revealing that the integration 
of encapsidated genomes into the ERGIC promotes the 
development of the viral particle [3, 12, 13]. Moreover, the 
S proteins are incorporated into virions at this step. Besides, 
the M proteins bind to the nucleocapsid that improves the 
completion of the virions assembly. Finally, the virion is 
transferred outside of the cell and releases through exocy-
tosis [3, 9].
Viral receptors
Penetrating to the target cell is a crucial point in the repli-
cation cycle of SARS-CoV-2. The primary marker of this 
stage is an adequate attachment of the S glycoprotein to a 
cell surface receptor [14, 15]. S1 ward is implicated in recep-
tor attaching which includes N- and C-terminal domains 
that both may play as the receptor-binding domain (RBD), 
having significant determinants of cell tropism located in 
S1-CTD region. The elongated S2 domains of stalk form 
the spike trimer are essentially implicated in starting the 
integration of the viral envelope and membranes of the target 
cell. SARS-CoV-2 binds to special cellular receptors via the 
S protein, that makes deformation of the S proteins and then 
intercedes the fusion among the viral and cell membranes, 
leading to discharging the nucleocapsid into the host cell 
[16, 17].
Fig. 1  Schematic overview 
of the SARS-CoV-2 replica-
tive cycle. This replication 
cycle is divided into multiple 
steps: attachment and entry, 
replication of virus replica-
tion, genome transcription and 
replication, structural protein 
translation, and assemblage and 
release of the virus. SARS-
CoV-2 severe acute respiratory 
syndrome coronavirus 2, sgRNA 
single guide RNA, gRNA 
guide RNA, ER endoplasmic 
reticulum, ERGIC ER-Golgi 
intermediate compartment
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Receptor attachment is the principal marker of the host 
spectrum and tissue tropism of coronavirus. Coronavirus 
has acquired cell surface factors as receptors, for example, 
aminopeptidase N (APN) for 229E, angiotensin-converting 
enzyme 2 (ACE2) for SARS as well as SARS-CoV-2, dipep-
tidyl peptidase 4 (DPP4) for MERS and O-acetylated sialic 
acid for OC43. Host proteases mediate the activation of S 
protein, for example, activation of S protein of SARS-COV-2 
requires further cleavage by the endosomal cysteine protease 
cathepsin L and another trypsin-like serine protease [18–20].
Furthermore, S protein of SARS-CoV-2 encompasses 
two cleavage locations for furin which is a ubiquitously 
expressed protease [21]. Besides the above-mentioned pro-
teases, extracellular, cell surface-related, and lysosomal ones 
have an essential impact on SARS-CoV-2 entry via trig-
gering the integration of S protein [18–21]. In the case of 
SARS-CoV-2, the integration of viral and cellular membrane 
is initiated following the S protein cleavage via cell surface-
related TMPRSS2) (transmembrane protease, serine 2) [22]. 
The same protease is required for cleavage and promotion of 
the 229E and MERS S protein [23].
Innate immunity
The innate immunity is a well-maintained defense mecha-
nism for accelerated recognition and control of pathogens 
and subsequent promotion of the adaptive immune response. 
Sufficient trigger of the innate immunity depends on detect-
ing the pathogen molecular patterns (PAMPs) via pattern 
recognition receptors (PRRs), including Toll-like receptors 
(TLRs), RIG-I-like receptors (RLRs), NOD‐like recep-
tor (NLR), C‐type lectin‐like receptors, and free‐molecule 
receptors in the host cytoplasm [24].
Following the promotion via PAMPs, PRRs absorb adap-
tor proteins, that comprise complex signaling pathways 
involving several kinases [25]. This signaling pathway even-
tually results in the promotion of the essential transcription 
factors, such as the nuclear factor interferon regulatory fac-
tor 3 (IRF3), Nuclear factor-kappa B (NF-κB), and Activa-
tor Protein-1(AP-1) [25, 26]. Synergistically, these agents 
release type I interferons that are secreted and act nearby 
interferon α/β Receptor (IFNAR). The antiviral effect of 
interferon type I has interfered through different mechanisms 
[27]. Additionally, chemokines and cytokines are ordered to 
stimulate inflammatory reactions, which is responsible for 
extensive tissue damage [26]. PAMPs include lipids, lipo-
proteins, proteins, and nucleic acids of bacterial, viral, para-
sitic, and fungal origin detected by TLRs [28]. Also, PAMPs 
recognition via TLRs can happen in cell membranes, lys-
osomes, endosomes, as well as endocytolysosomes. Over-
all, various TLRs could trigger different biological reactions 
via subsequent stimulation of several adapter proteins, like 
myeloid differentiation factor 88 (MyD88), TIR-domain-
containing adapter-inducing interferon-β (TRIP), Toll/inter-
leukin-1 receptor (TIR) domain-containing adapter protein 
(TIRAP) as well as TRIF-related-adaptor-molecule (TRAM) 
[25, 29].
Currently, just a limited report is available on the host 
innate immune status of SARS-CoV-2 infected patients. 
In one report where 99 cases in Wuhan were examined, 
increased total neutrophils (38%), diminished total lym-
phocytes (35%), increased serum IL-6 (52%) and enhanced 
c-reactive protein (84%) were detected [30]. Increased neu-
trophils and diminished lymphocytes also associate with 
the disease severity and mortality in COVID-19 patients 
[6]. Furthermore, patients needing ICU care had raised 
plasma levels of several innate cytokines to include IP-10, 
MCP-1, MIP-1A, and TNFα [31]. These clinical charac-
teristics intimated the likelihood of involvement of highly 
pro-inflammatory statuses in the disease progression and 
severity. This early sharp rise in the serum levels of pro-
inflammatory cytokines has also been reported in SARS-
CoV and MERS-CoV infection, implying a potential similar 
cytokine storm-mediated disease severity. The robust innate 
immune response toward viral infection relies profoundly 
on the interferon (IFN) type I responses and its downstream 
cascade that completes in managing viral replication and 
initiation of the effective adaptive immune response [32, 33].
Immune cells involvement
Macrophages and dendritic cells play a crucial role in the 
innate immune and adaptive immune responses. These cells 
can stimulate T lymphocytes and B lymphocytes, therefore 
induce coupling promoting innate and adaptive immunity. 
The immature dendritic cell has a high migration capac-
ity, and mature dendritic cells could considerably trigger 
T cells in the central link of regulation and maintaining the 
immune responses. Dendritic precursor cells are differen-
tiated into dendritic cells via adjusting inducers; such as 
granulocyte–macrophage colony-stimulating factor, inter-
leukin-4 (IL‐4), and tumor necrosis factor-alpha (TNF‐α) 
[34, 35]. CD4 positive T cells and CD8 positive T cells have 
an essential function by adjusting immune reactions toward 
viruses and the risk of autoimmunity and inflammation [36]. 
CD4 positive T cells elevate the production of virus‐specific 
antibodies via stimulating T‐dependent B cell activation [37] 
and, CD8 positive T cells are cytotoxic and can kill the cells 
infected with the virus [38].
Additionally, T helper cells generate proinflammatory 
cytokines via the nuclear factor kappa B (NF‐kB) signal-
ing pathway [39]. Interleukin 17 (IL‐17) cytokines call up 
monocytes and neutrophils to the infected area through 
inflammation and stimulate other downstream cytokine 
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and chemokine cascades, including Interleukin 1 (IL‐1), 
Interleukin 6 (LL‐6), Interleukin 8 (IL‐8), Interleukin 
21 (IL‐21), TNF‐beta, and monocyte chemoattractant 
protein-1 (MCP‐1) [40, 41]. Such information has been 
considered for related vaccine design and therapeutics 
developing studies [42]. Recently, it has been demon-
strated that T cell response to SARS S protein and other 
structural proteins (e.g., the M and N proteins) is long‐
lasting, suggesting that the design of vaccines based of 
viral structural proteins could stimulate dominant, effec-
tive, and long‐term memory responses toward virus [43]. 
A recent finding shows that humoral immunity is neces-
sary for controlling the persistent phase of coronavirus 
malady [44, 45]. Current evidence well-indicate that Th1 
type response is key to the reliable control of SARS-CoV 
and MERS-CoV and presumably valid for SARS-CoV-2 
as well. Similar findings of distinct CD8 + T cells have 
been reported during the MERS-CoV clearance in a mouse 
model too. Consequently, this knowledge can be beneficial 
in the case of SARS-CoV-2, as well. However, in the case 
of SARS-CoV-2 recent reports propose that the PBMCs 
of SARS-CoV-2 infected individuals have shown adequate 
mitigation in the CD8 + and CD4 + T cell counts, which 
may result in compromised T memory cell production and 
persistence in SARS-CoV-2 survivors [46].
The complement system has a critical function in the 
immune responses to infection caused by the coronavirus 
since this system enables the detection and response to 
viral particles. Considering its potency to harm the host 
tissues, the complement system is regulated via inhibiting 
proteins of serum. C3a and C5a show a proinflammatory 
activity that could initiate the recruitment of the inflam-
matory cell, such as activation of neutrophil cells [47]. 
Blocking C3a and C5a could be a treatment for severe lung 
damage, and the anti‐C5a antibody has shown to save the 
mice from MERS infection [2]. Activation of complement 
and the contact system, through the formation of brady-
kinin, may perform a role in the SARS-CoV-2-induced 
pulmonary edema, and its recommended that further work 
is necessary to verify the information. Although comple-
ment is sufficient in defending against various viruses, it 
does not seem to be protective against the coronavirus. C3 
knockout mice contaminated with SARS-CoV had fewer 
lung disease than wild-type mice, proposing, that comple-
ment may have a role in coronavirus pathogenesis. Some 
evidence suggests that revealed pulmonary edema may be 
bradykinin-induced and could be the reason that corticos-
teroids, antihistamines, and other traditional mediations 
for edema are not sufficient. ACE2 is a co-receptor for 
SARS-CoV-2, and studies so far have not achieved a ben-
efit or risk correlated with the application of either ACE-
inhibitors or angiotensin receptor antagonists [48].
Interferons
Macrophages are critical producers of type I interferons 
and other pro-inflammatory cytokines which trigger anti-
viral protection, even though they potentially contribute 
to immune pathology mediated to viral infections [49]. 
Interferons mediate direct antiviral influences that restrict 
viral replication via activating/regulating a group of well-
defined antiviral effectors, such as protein kinase R (PKR) 
and Ribonuclease L (RNase L), while inflecting other fac-
ets of the innate and adaptive immune responses via stimu-
lating a wide variety of interferon-inducible genes [50].
There are two main pathways via them host cells sense 
invading viruses and trigger the interferon pathway; the 
cytoplasmic interferon induction pathways and TLR asso-
ciated pathway [51]. TLRs including TLR3, TLR7, TLR8 
as well as TLR9 could recognize viruses in endosomal 
compartments as they penetrate cells [52]. In contrast, 
cytoplasmic caspase activation and recruitment domain 
(CARD) RNA helicases, RIG-I, and melanoma differenti-
ation-associated gene 5 (Mda5), identify viral RNAs in the 
cytoplasm [53]. Pathways are activated by PAMPs, includ-
ing double-stranded RNA, that is a byproduct of virus rep-
lication or constructed single-stranded RNAs mediated to 
incoming viral genomes, being common objective [54]. 
The cytoplasmic interferon induction pathways and TLR 
use various adaptor proteins to mediate signaling, with 
the TLR dependent pathways applying MyD88 and TRIF. 
Downstream of the multiple adaptors, these pathways 
share some typical signaling molecules and transcription 
factors, for example; interferon regulatory factor 3 (IRF-
3), activator protein-1 as well as NF-kB for initiation the 
type I interferon expression. Subsequently, type I interfer-
ons induce the Janus kinase/signal transducers and activa-
tors of transcription (JAK‐STAT) signal pathway, which 
enhances the transcription of genes induced by interfer-
ons [55]. Interferons restrict the spread of virus particles 
and have an immunomodulatory activity to improve the 
phagocytosis by macrophage cells, as well as restriction 
of natural killer’s function to infected target cells and T 
and B lymphocytes [56].
The viral nucleic acids subsequent infecting plasma‐like 
dendritic cells are detected via TLR7 and TLR9 to trigger 
the inflammatory cytokine formation and type I interferons 
associated with IRF as well as NF‐κB. Although corona-
viruses are susceptible to interferon α and β, these viruses 
persist highly pathogenic in this situation [55]. However, 
the N proteins of SARS play as an antagonist for immune 
escape protein and interferon reactions of the host. Com-
paring with SARS-CoV, which is thought to induce inad-
equate interferon response, SARS-CoV-2 robustly triggers 
the expression of numerous IFN-inducible genes (ISGs). 
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These ISGs display immunopathogenic potentials, defined 
by the overrepresentation of genes implicated in inflam-
mation [57].
Chemokine and cytokine
The C-X-C motif of chemokine 10 (CXCL10) and C–C 
motif of Chemokine Ligand 3 (CCL3) are formed as the 
earliest chemokines following viral infection. CXCL10 over-
expression in the central nervous system by a murine coro-
navirus demonstrated that exaggerated natural killer cells 
aggregation in immunodeficient recombination activating 
gene 1 (RAG1) negative/negative mice could be involved 
in the virus clearance. Despite the primary natural killer 
cell recruitment, there are few documents of a direct anti-
viral activity for wild type virus. Their potential to secrete 
interferon-γ can enhance the presentation of antigen through 
regulation of major histocompatibility complex class I 
(MHC 1) and class II (MHC 2) molecules [58, 59].
Augmented CCL3 has shown to be associated with the 
innate and adaptive immune reactions via inducing recruit-
ment, promotion as well as the maturation of dendritic cells 
and T lymphocytes. Cytokines like IL-1α, IL-1β, IL-6, as 
well as IL-12 rapidly produce in the corona infected cells 
like. TNF-α, IL-12, as well as IL-1β are formed in resident 
host cells in reply to virus infection. Stimulation of adaptive 
immune reactions can change the composition and expres-
sion of infiltrating cells and chemokine in the viral infection 
site. Although C-X-C motif chemokine 9 (CXCL9), C–C 
Motif Chemokine Ligand 2 (CCL2), CCL3, C–C Motif 
Chemokine Ligand 4 (CCL4), C–C Motif Chemokine 
Ligand (CCL5), and C–C Motif Chemokine Ligand (CCL7) 
are formed in acute viral infection, CXCL9 and CXCL10 
can gather the activated T cells and natural killers. Over-
all, CXCL10 is indicated to be the sustained and major 
chemokine in viral infection [59].
As shown by the recent studies, increased circulating lev-
els of pro-inflammatory cytokines (e.g., Interferon γ, inter-
leukin (IL-) 1B, IL-6, IL-12) and chemokines (CXCL10, 
and CCL2) are correlated with pulmonary inflammation 
and extensive lung involvement in SARS patients, similarly 
to what occurs in MERS-CoV infection [60]. Huang et al. 
[34] recently reported that infected patients with COVID 19 
also show enhanced levels of pro-inflammatory cytokines 
and chemokines. The demonstration of increased levels of 
IL-1B, IFNγ, CXCL10, and CCL2 firmly pointed toward the 
activation of T-helper-1 (Th1) cell function. More impor-
tantly, the so-called “cytokine storm” emerged as the prin-
cipal factor driving a more severe clinical course. This idea 
has been originated from the observation that COVID-19 
patients requiring ICU admission revealed higher concentra-
tions of CXCL10, CCL2, and TNFα as compared with those 
in which the infection was less severe and did not require 
ICU admission. To further complicate the issue, it should 
be highlighted that in patients with SARS-Cov-2 infection, 
as a difference from SARS-CoV infection, there is also an 
enhanced secretion Th2-immune-oriented cytokines such as 
IL-4 and IL-10, whose main effect is to repress inflamma-
tion [60].
Cytopathic effects
Although host airway epithelial cells provide a primary aim 
for infection, dendritic cells in the respiratory epithelium 
are sentinels of the host immune reactions that detect viral 
pathogens and present their antigens to T cells. It has been 
found that 229E triggers massive cytopathic effects (CPE) 
in dendritic cells, for example, the large syncytia and cell 
death. Monocyte is more resistant against viral infection and 
CPE of 229E because of the expression levels of CD13 (one 
membrane receptor for 229E) is similar, and cell death and 
CPE are acquired after 24 h of the 229E infection of mono-
cytes. Cell death stimulated by 229E is independent from 
TNF-α, Fas ligand (FasL), TNF-related apoptosis-inducing 
ligand (TRAIL), as well as caspases, confirming that viral 
replication is the causative agent of the CPE. The result of 
dendritic cell death at the initial step of 229E infection might 
affect the central control of virus release and the establish-
ment of persistent immune memory, therefore the individu-
als could be reinfected again by 229E [61].
Kidney cell lines from African green, cynomolgus, and 
rhesus monkey have demonstrated to be sensitive toward 
SARS infection. Additionally, in a study by Kaye et al. it was 
shown that kidney cells derived from a buffalo green mon-
key were actively infected with SARS, with titers up to 4.7 
log10/mL higher than input SARS virus, like the levels in 
other monkey kidney cells. They showed that the most mon-
key kidney–derived cell lines like Vero E6, assisted SARS 
replication, having titers 3.9–4.7 log10/mL higher than input 
SARS virus titers [62, 63].
High titers of SARS available in these cells must be 
regarded while applying them for virus isolation, and proper 
safety guidelines must be pursued. The capacity of SARS 
to replicate effectively in kidney cell lines could be due to 
the presence of ACE-2 receptors in the kidney [64]. Also, 
ACE-2 is expressed in gastrointestinal, lung, as well as heart 
tissue [65]. The primate kidney cell lines are specifically 
sensitive toward SARS infection. This virus has been col-
lected from the kidney of an infected human, so it has been 
proposed that human kidney cell lines could also provide 
replication of SARS [66]. In a report by Kaye et al., it was 
found that SARS could be collected in various cell lines, 
indicating that this virus could acquire high titers across 
multiple cell lines, even in the absence of CPE [62]. The 
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relative contributions of virus replication and cytopathic 
effects or immunopathological host responses to the severe 
and fatal consequences of COVID-19 lung infections have 
as yet to be determined. In a pioneer study, Schifanella et al. 
showed that SARS-CoV-2 replication and cytopathic effects 
in type II alveolar pneumocytes make focal lung damage in 
a somebody with no history of pulmonary symptoms [67].
Autoimmunity
Autoimmune diseases occur as a consequence of atypical 
immune reactions for the detection of non- and self-antigens 
[68]. Until now, up to 80 autoimmune diseases have been 
identified [69]. Many agents have been mediated to autoim-
mune diseases like age, genetics, and infection [70].
Interestingly, viral agents are being regarded as main 
infective agents which induce the autoimmune diseases in 
sensitive people, and some strategies have been offered to 
define the interrupt self-tolerance in the host by various 
viral infections. Multiple processes have been suggested for 
initiating and triggering the autoimmune disease induced 
virus. Molecular mimicry is the most probable process and 
happens when a virus antigen mimics a host antigen and 
stimulates cross-reactive T lymphocytes. Epitope spreading 
is another process, for example, the destruction of host tis-
sue due to T lymphocyte activation unique to the virus has 
shown to induce promoting autoreactive T lymphocytes and 
liberation of self-antigens surrounded the inflammatory site. 
Bystander promotion is the stimulation of autoreactive T 
lymphocytes because of the cytokine formation in immune 
reactions targeted by the virus. Also, encrypted antigens 
from the host are formed from particular tissues during tis-
sue damage targeted by the virus. Additionally, superanti-
gens stimulate a wide variety of nonspecific T lymphocyte 
clones. It has been found that coronavirus, parainfluenza, 
and metapneumovirus are significantly mediated to rheu-
matoid arthritis. Rheumatoid arthritis is an autoimmune 
disorder contributing to interactions between environmen-
tal and genetic agents. It has been reported that rheumatoid 
arthritis due to the formation of autoantibodies in genetically 
susceptible individuals could be triggered by some driving 
factors like the virus [71]. However, an association between 
respiratory viral infections like coronavirus and developing 
rheumatoid arthritis is proposed [72].
It has been found that CD 4 positive and CD8 positive T 
lymphocytes can link the demyelination in vivo, for exam-
ple, rodents Theiler’s encephalomyelitis viral infection and 
murine coronavirus [73]. Additionally, some reports have 
declared that CD8 T lymphocytes distinct to myelin could 
stimulate a progressive type of experimental autoimmune 
encephalomyelitis (EAE). Also, these cells account for 
major infiltrating immune cells in demyelinating lesions 
in multiple sclerosis individuals. Moreover, CD8 posi-
tive T lymphocytes stimulate demyelination in Theiler’s 
encephalomyelitis virus infection in vivo. Reduced level 
of demyelination has been identified in CD4 positive T 
lymphocytes deficient mice infected by murine corona-
virus infection, which is consistent with an activity for 
CD8 positive T lymphocytes. In a study by Pewe et al. 
their findings support the notion that CD8 positive T lym-
phocytes can associate with demyelination independent 
to CD4 positive T lymphocytes. Also, they found that 
interferon-γ is significant for demyelination mediated 
to CD8 positive T lymphocyte. Demyelination was not 
diminished when depleted interferon-γ negative/negative 
splenocytes were translocated [74].
Interferon-γ has many impacts on inflammation in the 
central nervous system, for example, as a proinflamma-
tory molecule and in adjusting the trafficking of leukocyte 
cells and the population dynamics of T lymphocyte [75]. 
Interferon-γ, in pro-inflammatory activity, is participated 
in roles including activation macrophage cells, adjusting 
MHC I and II transcription, and stimulating adhesion mol-
ecules necessary for their penetrating the central nervous 
system. Also, interferon-γ is contributed to the stimulation 
of chemokines expression, such as CCL2, CCL7, CCL4, 
CCL5, CXCL9, and CXC L10, that are chemoattractants 
for monocytes and lymphocytes and are up-regulated in 
infected mice central nervous system [74]. Overall, these 
findings show that interferon-γ is important for demyelina-
tion associated with CD8 positive T lymphocytes in mice 
infected by murine coronavirus because of macrophage 
activation, and migration inside the central nervous 
system.
Channappanavar et al. has reported a pathogenic cascade 
that drives to ARDS and death; this mechanism is possible 
operative in COVID-19 infections. That study suggest a sce-
nario in which viral replication leads to a delayed interferon 
response, accumulation, and activation of monocyte/mac-
rophages and neutrophils, which in aggregate result in an 
excessive immune response accountable for the alveolar and 
endothelial apoptosis [76]. There is certainly a complexity 
in the participation of type I IFNs concerning early and late 
responses. The former may limit virus replication through 
induction of interferon-stimulated genes. At the same time, 
the latter can worsen disease by heightening the recruitment 
and function of macrophages and other innate immune cells 
[77]. The dysregulation of inflammatory responses starts 
pulmonary injury that leads to ARDS. Patients admitted for 
severe COVID-19 infections should probably hold main-
tenance therapies; these judgments are properly left to the 
rheumatology/infectious disease teams using care of them. 
Rheumatologists and infectious disease experts should be 
managing concurrently in this epidemic as precise data are 
not accessible, thus making recommendations speculative.
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Host factors
People at the highest risk for severe corona infection com-
prise individuals aged > 60 years and, those with underlying 
situations like diabetes, hypertension, cardiovascular disorder, 
cancer as well as a chronic respiratory disease. Surprisingly, 
COVID infection in infants noted to be relatively mild and rare, 
with up to 2.4% of the cases. Additionally, mortality increases 
with age, having the highest rate in individuals > 80 years. 
Based on findings and analysis, it has found that males are 
more at risk than females [78]. Although males and females 
have been infected at equal rates, the death number in males 
was 2.8%, compared with 1.7% among females. Additionally, 
the crude death ratio is higher among males (4.7%) in com-
parison with females (2.8%) [79].
When a woman is pregnant, her body and immune system 
naturally become weak, consequently, the mother could be 
infected more easily. Pregnant women experience immuno-
logic and physiologic alterations, which might make them 
more susceptible to respiratory infections such as COVID19 
[80]. Some individuals are at risk for corona infections, includ-
ing chronic respiratory patients (like chronic obstructive pul-
monary disease, asthma, emphysema, bronchitis), as well as 
chronic heart patients (like heart failure, chronic kidney dis-
order), people with chronic liver disorder (like hepatitis), and 
chronic neurological conditions patients (such as Parkinson, 
motor neuron disorder, multiple sclerosis) [81].
Obesity is a type of sustained low-grade inflammation. 
Along with serving as an energy-storage depot, adipose tis-
sue has endocrine activities, forming adipokines with immu-
nomodulatory influences [82]. Leptin is a proinflammatory 
adipokine expressed in the lung, predominantly produced 
by white adipose which contributes to physiological condi-
tions including maturation [83]. It is also involved in respira-
tory control and pathological conditions, including Chronic 
Obstructive Pulmonary Disease (COPD), obstructive sleep 
apnoea, inside the respiratory system [84]. Obesity sufferers 
show high circulating rates of leptin that potentially mediated 
via the up-regulation of suppressor of cytokine signalling-3. 
Also, interferon expression happens by the same JAK-STAT 
signaling pathway which is negatively controlled through sup-
pressor of cytokine signalling-3, suggesting a critical path-
way by which interferon reactions are attenuated against res-
piratory viruses in obese individuals [85]. Table 1 presents 
some of the important host factors involved in the coronavirus 
pathogenesis.
Genetics of hosts
Viruses usually demonstrate a difference in gaining sen-
sitivity and clinical manifest, indicating that virus patho-
genesis could have resulted from complicated intercom-
munication between viruses and hosts. This variability 
upon infection has been mediated to a range of agents like 
viral strain and sequence variation, age, immune status, 
and the genetic background of the host. Innate antiviral 
immunity prepares the primary line of protection toward 
pathogenic invasions by sensing PAMPs via PRRs. For 
example, activation of the cytoplasmic DNA sensor stimu-
lates the formation of interferon to defend against viruses, 
which is also significant for the establishment of inter-
ferons in mousepox infection [96]. Interferons impede 
the replication of the virus via stimulating hundreds of 
Interferon-induced genes that control activities of antiviral 
influencers [97].
Variations in the genetic material of the multiple innate 
immune pathway genes, which cause antiviral effector 
activities influence the infection [98]. In the midst of 
interferon-stimulated genes, interferon-stimulated trans-
membrane proteins, expressed at the plasma membrane 
and membrane of endocytic vesicles, limit many other 
enveloped virus infections through inhibition of the viral 
envelope fusing with membranes of cells. Interferon-
induced Transmembrane-3 variants that diminish gene 
expression or encode truncated forms are connected to a 
higher risk of influenza disease and a more serious health 
condition [99]. Host cells apply RNase L to destroy viral 
RNA and stimulate the formation of interferon through 
RIG-I to protect against RNA viruses [51].
Contrasted to another + RNA viruses, coronaviruses 
have a particularly large genome and employ a complex 
genome expression approach. Next to a role in funda-
mental virus replication or virus assembly, various of the 
coronavirus proteins expressed in the infected cell play a 
part into the coronavirus-host interplay. For instance, by 
interacting with the host cell to generate optimal condi-
tions for coronavirus replication, via modifying host gene 
expression or by hindering the host’s antiviral defenses 
[100]. These SARS-CoV-2–host interplays are essential to 
viral pathogenesis and will eventually determine the con-
sequence of infection. Due to the intricacy of the SARS-
CoV-2 proteome and replication cycle, our understanding 
of host determinants implicated in coronavirus replication 
is yet in an initial step compared to what is understood for 
some other + RNA viruses.
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Conclusion
The knowledge about coronavirus, including replication of 
the virus, cell biology, and pathogenesis has an accelerated 
progress rate because of the availability of reverse genet-
ics systems. Currently, the raised interest in this class of 
viruses is due to the COVID-19 pandemic, and resources 
have been provided for studying these viruses. The impres-
sive speed by which the COVID-19 was identified, and the 
genome was sequenced, along with the earlier accumu-
lated data on the other members of the corona-virus fam-
ily, has provided a lot of new insight about this universal 
health issue. There are still many significant and intrigu-
ing aspects remaining to be identified about COVID-19. 
Since coronaviruses appear with a periodical pattern, and 
unpredictably disperse quickly as well as stimulated severe 
disorders, they are regarded as a constant threat to human 
life. There are no approved vaccines or drugs for remedy-
ing coronaviruses disorders, and many animal reservoirs 
for coronaviruses and recombinant coronaviruses are exist-
ing. Future directions for COVID-19 studies include the 
further gaining knowledge of the replication mechanisms; 
clarifying the virulence molecular determinants and tro-
pism, and the immune reactions. These studies should have 
special regard toward probable activities of group-specific 
proteins; developing vaccine techniques and antiviral 
drugs for human viruses. Although many new insights 
have been provided in regard to the COVID-19, it is still 
very critical to study about the isolation and definition of 
new coronaviruses with pathogenic potential for humans.
Table 1  Host factors involved in the coronavirus pathogenesis
SARS-CoV severe acute respiratory syndrome coronavirus, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2, HCoV-NL63 human 
coronavirus NL63, MERS-CoV middle east respiratory syndrome coronavirus, HCoV-OC43 human coronavirus OC43, HCoV-HKU1 human 
coronavirus HKU1, IBV infectious bronchitis virus, HCoV-229E human coronavirus 229E, MHV mouse hepatitis virus, ACE2 angiotensin-con-
verting enzyme 2, TMPRSS transmembrane protease, serine 2; APN aminopeptidase N, IFITM2 interferon induced transmembrane protein 2, 
IFITM3 interferon induced transmembrane protein 3, GBF1 golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1, ARF1 
ADP ribosylation factor1
Stage Virus Host factor Function References
Attachment and entry SARS-CoV, SARS-CoV-2 ACE2/ TMPRSS11D Attachment/ S1/S2 cleavage to 
activate the S protein
[86]
Attachment and entry HCoV-NL63 ACE2 Attachment and entry [87]
Attachment and entry MERS-CoV dipeptidyl-peptidase 4 (DPP4), 
Furin
Attachment and entry [88]
Attachment and entry HCoV-OC43, HCoV-HKU1 9-O-acetylated sialic acid Attachment and entry [89]
Attachment and entry IBV Sialic acid/Furin Attachment / S1/S2 cleavage to 
activate the S protein
[90]
Attachment and entry HCoV-229E APN /TMPRSS11D Attachment/ S1/S2 cleavage to 
activate the S protein
[90]
Attachment and entry HCoV-OC43 acetyl-9-O-acetylneuraminic 
acid/ IFITM2 and IFITM3
Attachment/ Promote virus 
entry
[91]
Translation of replicase and 
viral replication-transcription 
complexes (RTCs) Assembly
IBV Annexin A2 Modulate the frameshifting effi-
ciency of viral RNA, Serve as 
the template for an anti-viral 
cellular protein
[92]
Translation of replicase and 
viral replication-transcription 
complexes (RTCs) Assembly
MHV GBF1 and ARF1 Required for efficient MHV 
RNA replication
[93]
Translation of structural proteins SARS-CoV N-linked glycosylation enzymes Post-translation modification of 
structural
Proteins such as S, M
[94]
Translation of structural proteins MHV O-linked glycosylation enzymes Post-translation modification of 
structural
Proteins such as M protein
[94]
Virion assembly and budding HCoV-229E, HCoV-NL63 β-tubulin β-tubulin interact with S 
proteins
and reinforcement successful 
assembly and budding
[94]
Virion assembly and budding IBV β-actin β-actin interact with M proteins 
which involved in the virion 
assembly and budding
[95]
5374 Molecular Biology Reports (2020) 47:5365–5376
1 3
Acknowledgements Thanks to guidance and advice from “Clinical 
Research Development Unit of Baqiyatallah Hospital”. There was a 
page limitation for all the other works, therefore we have to apolo-
gize from the authors whose works could not receive a citation in this 
manuscript.
Funding No grant or financial support was devoted to this project by 
any organization.
Compliance with ethical standards 
Conflict of interest Nothing declared.
Research involving human participants and/or animals No human or 
animal was involved in this study.
Informed consent There was no human participant and consent was 
not required.
References
 1. Denison MR et al (2011) Coronaviruses: an RNA proofreading 
machine regulates replication fidelity and diversity. RNA Biol 
8(2):270–279
 2. Li G et al (2020) Coronavirus infections and immune responses. 
J Med Virol 92(4):424–432
 3. Fehr AR, Perlman S (2015) Coronaviruses: an overview of their 
replication and pathogenesis. Methods Mol Biol (Clifton, NJ) 
1282:1–23
 4. To KKW et al (2013) From SARS coronavirus to novel animal 
and human coronaviruses. J Thorac Dis 5(Suppl 2):S103–S108
 5. Skariyachan S et al (2019) Recent aspects on the pathogenesis 
mechanism, animal models and novel therapeutic interventions 
for Middle East respiratory syndrome coronavirus infections. 
Front Microbiol 10:569
 6. Wu F et al (2020) A new coronavirus associated with human 
respiratory disease in China. Nature 579(7798):265–269
 7. Organization, T.W.H. (2019) Coronavirus disease (COVID-19) 
outbreak situation. https ://www.who.int/emerg encie s/disea ses/
novel -coron aviru s-2019.
 8. Weiss SR, Leibowitz JL (2011) Coronavirus pathogenesis. Adv 
Virus Res 81:85–164
 9. Liang Y et al (2020) Highlight of immune pathogenic response 
and hematopathologic effect in SARS-CoV, MERS-CoV, and 
SARS-Cov-2 infection. Front Immunol 11:1022
 10. Skariyachan S et al (2019) Recent aspects on the pathogenesis 
mechanism, animal models and novel therapeutic interventions 
for middle east respiratory syndrome coronavirus infections. 
Front Microbiol 10:569–569
 11. Mousavizadeh L, Ghasemi S (2020) Genotype and phenotype 
of COVID-19: their roles in pathogenesis. J Microbiol Immunol 
Infect S1684-1182(20)30082–7.
 12. Li F (2016) Structure, function, and evolution of coronavirus 
spike proteins. Annu Rev Virol 3(1):237–261
 13. Belouzard S et al (2012) Mechanisms of coronavirus cell entry 
mediated by the viral spike protein. Viruses 4(6):1011–1033
 14. Li F (2016) Structure, function, and evolution of coronavirus 
spike proteins. Annu Rev Virol 3:237–261
 15. Yuki K, Fujiogi M, Koutsogiannaki S (2020) COVID-19 
pathophysiology: a review. Clin Immunol (Orlando, Fla) 
215:108427–108427
 16. Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, Zhou Y, 
Du L (2020) Characterization of the receptor-binding domain 
(RBD) of 2019 novel coronavirus: implication for development 
of RBD protein as a viral attachment inhibitor and vaccine. 
Cell Mol Immunol 17(6):613–620
 17. Chen WH, Hotez PJ, Bottazzi ME (2020) Potential for develop-
ing a SARS-CoV receptor-binding domain (RBD) recombinant 
protein as a heterologous human vaccine against coronavirus 
infectious disease (COVID)-19. Hum Vaccine Immunother p. 
1–4.
 18. Bosch BJ, Smits SL, Haagmans BL (2014) Membrane ecto-
peptidases targeted by human coronaviruses. Curr Opin Virol 
6:55–60
 19. Wan Y et al (2020) Receptor recognition by the novel coronavirus 
from wuhan: an analysis based on decade-long structural studies 
of SARS coronavirus. J Virol 94(7):e00127–e220
 20. Liu, D.X., J.Q. Liang, and T.S. Fung, Human Coronavirus-229E, 
-OC43, -NL63, and -HKU1. Reference Module in Life Sciences, 
2020: p. B978-0-12-809633-8.21501-X.
 21. Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler 
D (2020) Structure, function, and antigenicity of the SARS-
CoV-2 spike glycoprotein. Cell
 22. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, 
Erichsen S, Schiergens TS, Herrler G, Wu N-H, Nitsche A (2020) 
SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is 
blocked by a clinically proven protease inhibitor. Cell
 23. de Wilde AH et al (2017) Host factors in coronavirus replication. 
In: Trip RA, Tompkins SM (eds) Roles of host gene and non-
coding RNA expression in virus infection. Springer, New York, 
pp 1–42
 24. Frieman M, Heise M, Baric R (2008) SARS coronavirus and 
innate immunity. Virus Res 133(1):101–112
 25. Mogensen TH (2009) Pathogen recognition and inflamma-
tory signaling in innate immune defenses. Clin Microbiol Rev 
22(2):240–273
 26. Iwanaszko M, Kimmel M (2015) NF-κB and IRF pathways: 
cross-regulation on target genes promoter level. BMC Genom-
ics 16(1):307–307
 27. Perry AK et al (2005) The host type I interferon response to viral 
and bacterial infections. Cell Res 15(6):407–422
 28. Kawai T, Akira S (2011) Toll-like receptors and their crosstalk 
with other innate receptors in infection and immunity. Immunity 
34(5):637–650
 29. Yamamoto M, Takeda K, Akira S (2004) TIR domain-containing 
adaptors define the specificity of TLR signaling. Mol Immunol 
40(12):861–868
 30. Zhou P et al (2020) A pneumonia outbreak associated with a new 
coronavirus of probable bat origin. Nature 579(7798):270–273
 31. Huang C et  al (2020) Clinical features of patients infected 
with 2019 novel coronavirus in Wuhan, China. Lancet 
395(10223):497–506
 32. Mahallawi WH et al (2018) MERS-CoV infection in humans 
is associated with a pro-inflammatory Th1 and Th17 cytokine 
profile. Cytokine 104:8–13
 33. Prompetchara E, Ketloy C, Palaga T (2020) Immune responses in 
COVID-19 and potential vaccines: Lessons learned from SARS 
and MERS epidemic. Asian Pac J Allergy Immunol 38(1):1–9
 34. Chaplin DD (2010) Overview of the immune response. J Allergy 
Clin Immunol 125(2 Suppl 2):S3–S23
 35. Hiasa M et al (2009) GM-CSF and IL-4 induce dendritic cell 
differentiation and disrupt osteoclastogenesis through M-CSF 
receptor shedding by up-regulation of TNF-α converting enzyme 
(TACE). Blood J Am Soc Hematol 114(20):4517–4526
 36. Mason D (2001) T-cell-mediated control of autoimmunity. 
Arthritis Res 3(3):133–135
5375Molecular Biology Reports (2020) 47:5365–5376 
1 3
 37. Flynn S et al (1998) CD4 T cell cytokine differentiation: the 
B cell activation molecule, OX40 ligand, instructs CD4 T 
cells to express interleukin 4 and upregulates expression of the 
chemokine receptor, Blr-1. J Exp Med 188(2):297–304
 38. Zhang N, Bevan MJ (2011) CD8(+) T cells: foot soldiers of the 
immune system. Immunity 35(2):161–168
 39. Liu T et al (2017) NF-κB signaling in inflammation. Signal 
Transduct and Target Ther 2:17023
 40. Kany S, Vollrath JT, Relja B (2019) Cytokines in inflammatory 
disease. Int J Mol Sci 20(23):6008
 41. Turner MD et al (2014) Cytokines and chemokines: at the cross-
roads of cell signalling and inflammatory disease. Biochim Bio-
phys Acta 1843(11):2563–2582
 42. Sheikhshahrokh A et al (2020) Frontier therapeutics and vaccine 
strategies for sars-cov-2 (COVID-19): a review. Iran J Public 
Health 49:18–29
 43. Liu WJ et al (2017) T-cell immunity of SARS-CoV: implica-
tions for vaccine development against MERS-CoV. Antiviral Res 
137:82–92
 44. Dittel BN (2008) CD4 T cells: balancing the coming and going 
of autoimmune-mediated inflammation in the CNS. Brain Behav 
Immun 22(4):421–430
 45. Kuwabara T, Ishikawa F, Kondo M, Kakiuchi T (2017) The role 
of IL-17 and related cytokines in inflammatory autoimmune dis-
eases. Mediat Inflamm 2017
 46. Kumar S et al (2019) Host immune response and immunobiol-
ogy of human SARS-CoV-2 infection. Coronavirus Disease 2019 
(COVID-19) 2020:43–53
 47. Abou-El-Hassan H, Zaraket H (2017) Viral-derived complement 
inhibitors: current status and potential role in immunomodula-
tion. Exp Biol Med (Maywood, NJ) 242(4):397–410
 48. Maglakelidze N, Manto KM, Craig TJ (2020) A review: does 
complement or the contact system have a role in protection or 
pathogenesis of COVID-19? Pulm Ther 1
 49. Vadiveloo PK et  al (2000) Role of type I interferons dur-
ing macrophage activation by lipopolysaccharide. Cytokine 
12(11):1639–1646
 50. Sang Y, Miller LC, Blecha F (2015) Macrophage polarization in 
virus-host interactions. J Clin Cell Immunol 6(2):311
 51. Samuel CE (2001) Antiviral actions of interferons. Clin Micro-
biol Rev 14(4):778–809
 52. Lee BL, Barton GM (2014) Trafficking of endosomal toll-like 
receptors. Trends Cell Biol 24(6):360–369
 53. Barral PM et al (2009) Functions of the cytoplasmic RNA sen-
sors RIG-I and MDA-5: key regulators of innate immunity. Phar-
macol Ther 124(2):219–234
 54. Iwasaki A (2012) A virological view of innate immune recogni-
tion. Annu Rev Microbiol 66:177–196
 55. Lester SN, Li K (2014) Toll-like receptors in antiviral innate 
immunity. J Mol Biol 426(6):1246–1264
 56. Nan Y, Wu C, Zhang Y-J (2017) Interplay between Janus Kinase/
signal transducer and activator of transcription signaling acti-
vated by type I interferons and viral antagonism. Front Immunol 
8:1758–1758
 57. Zhou Z, Ren L, Zhang L, Zhong J, Xiao Y, Jia Z, Guo L, Yang 
J, Wang C, Jiang S (2020) Overly exuberant innate immune 
response to SARS-CoV-2 infection
 58. Phares TW et al (2013) Astrocyte-derived CXCL10 drives accu-
mulation of antibody-secreting cells in the central nervous sys-
tem during viral encephalomyelitis. J Virol 87(6):3382–3392
 59. Bergmann CC et al (2006) Coronavirus immunity: from T cells to 
B cells. In: Perlman S, Gallagher T, Snijder EJ (eds) The nidovi-
ruses. Springer, New York, pp 341–349
 60. Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M 
(2020) The cytokine storm in COVID-19: an overview of the 
involvement of the chemokine/chemokine-receptor system. 
Cytokine Growth Factor Rev
 61. Mesel-Lemoine M et al (2012) A human coronavirus responsi-
ble for the common cold massively kills dendritic cells but not 
monocytes. J Virol 86(14):7577–7587
 62. Kaye M et al (2006) SARS–associated coronavirus replication in 
cell lines. Emerg Infect Dis 12(1):128
 63. Müller MA et  al (2012) Human coronavirus EMC does 
not require the SARS-coronavirus receptor and maintains 
broad replicative capability in mammalian cell lines. mBio 
3(6):e00515-12
 64. Eckerle I et al (2013) In-vitro renal epithelial cell infection 
reveals a viral kidney tropism as a potential mechanism for acute 
renal failure during Middle East Respiratory Syndrome (MERS) 
Coronavirus infection. Virol J 10:359–359
 65. Hamming I et al (2004) Tissue distribution of ACE2 protein, the 
functional receptor for SARS coronavirus: a first step in under-
standing SARS pathogenesis. J Pathol 203(2):631–637
 66. Kaye M (2006) SARS-associated coronavirus replication in cell 
lines. Emerg Infect Dis 12(1):128–133
 67. Schifanella L et al (2020) Massive viral replication and cyto-
pathic effects in early COVID-19 pneumonia. arXiv:2005.00004.
 68. Mackay IR, Leskovsek NV, Rose NR (2008) Cell damage and 
autoimmunity: a critical appraisal. J Autoimmun 30(1–2):5–11
 69. Davidson A, Diamond B (2001) Autoimmune diseases. N Engl 
J Med 345(5):340–350
 70. Ercolini AM, Miller SD (2009) The role of infections in autoim-
mune disease. Clin Exp Immunol 155(1):1–15
 71. Smatti MK et al (2019) Viruses and autoimmunity: a review 
on the potential interaction and molecular mechanisms. Viruses 
11(8):762
 72. Joo YB et al (2019) Respiratory viral infections and the risk of 
rheumatoid arthritis. Arthritis Res Ther 21(1):199
 73. Oleszak EL et al (2004) Theiler’s virus infection: a model for 
multiple sclerosis. Clin Microbiol Rev 17(1):174–207
 74. Pewe L, Perlman S (2002) Cutting edge: CD8 T cell-mediated 
demyelination is IFN-γ dependent in mice infected with a neu-
rotropic coronavirus. J Immunol 168(4):1547–1551
 75. Rauch I, Müller M, Decker T (2013) The regulation of inflam-
mation by interferons and their STATs. JAK-STAT 2(1):e23820
 76. Channappanavar R, Perlman S (2017) Pathogenic human corona-
virus infections: causes and consequences of cytokine storm and 
immunopathology. In: Seminars in immunopathology. Springer, 
New York
 77. Askanase AD, Khalili L, Buyon JP (2020) Thoughts on 
COVID-19 and autoimmune diseases. Lupus Sci Med 
7(1):e000396–e000396
 78. Times, T.N.Y. Coronavirus threatens Americans with underlying 
conditions. https ://www.nytim es.com/2020/03/12/healt h/coron 
aviru s-midli fe-condi tions .html.
 79. The World Health Organization (2020) Report of the WHO-
China Joint Mission on Coronavirus Disease 2019 (COVID-19)
 80. Zhao X et al (2020) Analysis of the susceptibility to COVID-19 
in pregnancy and recommendations on potential drug screening. 
Eur J Clin Microbiol Infect Dis 1–12.
 81. Inform, N (2020) Coronavirus (COVID-19): social distancing. 
https ://www.nhsin form.scot/illne sses-and-condi tions /infec tions 
-and-poiso ning/coron aviru s-covid -19/coron aviru s-covid -19-
socia l-dista ncing .
 82. Mraz M, Haluzik M (2014) The role of adipose tissue immune 
cells in obesity and low-grade inflammation. J Endocrinol 
222(3):R113–R127
 83. Lago F et al (2007) The emerging role of adipokines as mediators 
of inflammation and immune responses. Cytokine Growth Factor 
Rev 18(3–4):313–325
5376 Molecular Biology Reports (2020) 47:5365–5376
1 3
 84. Tkacova R (2010) Systemic inflammation in chronic obstructive 
pulmonary disease: may adipose tissue play a role? Review of 
the literature and future perspectives. Mediat Inflamm 2010
 85. Almond MH et al (2013) Obesity and susceptibility to severe 
outcomes following respiratory viral infection. Thorax 
68(7):684–686
 86. Meng T et  al (2020) The insert sequence in SARS-CoV-2 
enhances spike protein cleavage by TMPRSS. bioRxiv
 87. Abdul-Rasool S, Fielding BC (2010) Understanding human coro-
navirus HCoV-NL63. Open Virol J 4:76
 88. Millet JK, Whittaker GR (2014) Host cell entry of Middle 
East respiratory syndrome coronavirus after two-step, furin-
mediated activation of the spike protein. Proc Natl Acad Sci 
111(42):15214–15219
 89. Hulswit RJ et al (2019) Human coronaviruses OC43 and HKU1 
bind to 9-O-acetylated sialic acids via a conserved receptor-
binding site in spike protein domain A. Proc Natl Acad Sci 
116(7):2681–2690
 90. Lim YX et al (2016) Human coronaviruses: a review of virus–
host interactions. Diseases 4(3):26
 91. Zhao X et al (2014) Interferon induction of IFITM proteins pro-
motes infection by human coronavirus OC43. Proc Natl Acad Sci 
111(18):6756–6761
 92. Kwak H, Park MW, Jeong S (2011) Annexin A2 binds RNA 
and reduces the frameshifting efficiency of infectious bronchitis 
virus. PLoS ONE 6(8):e24067
 93. Verheije MH et al (2008) Mouse hepatitis coronavirus RNA 
replication depends on GBF1-mediated ARF1 activation. PLoS 
Pathog 4(6):e1000088
 94. Fung TS, Liu DX (2019) Human coronavirus: host-pathogen 
interaction. Annu Rev Microbiol 73:529–557
 95. Wang J et al (2009) Interaction of the coronavirus infectious 
bronchitis virus membrane protein with β-actin and its implica-
tion in virion assembly and budding. PLoS ONE 4(3):e4908
 96. An P, Guo J-T, Winkler CA (2019) Editorial: Host Genet-
ics in Viral Pathogenesis and Control. Frontiers in genetics 
10:1038–1038
 97. Hoffmann H-H, Schneider WM, Rice CM (2015) Interferons 
and viruses: an evolutionary arms race of molecular interactions. 
Trends Immunol 36(3):124–138
 98. Fairfax BP et al (2014) Innate immune activity conditions the 
effect of regulatory variants upon monocyte gene expression. 
Science 343(6175):1246949
 99. Kenney AD et al (2017) Human genetic determinants of viral 
diseases. Annu Rev Genet 51:241–263
 100. de Wilde AH et al (2018) Host factors in coronavirus replication. 
Curr Top Microbiol Immunol 419:1–42
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
